U.S. Markets open in 5 hrs 3 mins

Surging Earnings Estimates Signal Good News for MercadoLibre (MELI)

Zacks Equity Research

MercadoLibre, Inc. MELI is an online trading platform in Latin America that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on MELI’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that MercadoLibre could be a solid choice for investors.

Current Quarter Estimates for MELI

In the past 30 days, two estimates have gone higher for MercadoLibre while one has gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 5 cents a share 30 days ago, to 18 cents today, a move of 260%.

Current Year Estimates for MELI

Meanwhile, MercadoLibre’s current year figures are also looking quite promising, with four estimates moving higher in the past month, compared to one lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 40 cents per share 30 days ago to 91 cents per share today, an increase of 127.5%.

MercadoLibre, Inc. Price and Consensus

MercadoLibre, Inc. Price and Consensus

MercadoLibre, Inc. price-consensus-chart | MercadoLibre, Inc. Quote

Bottom Line

The stock has also started to move higher lately, adding 15% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98% , +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MercadoLibre, Inc. (MELI) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research